Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...
Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.
Alnylam Pharmaceuticals Inc. won expanded US approval for a heart drug that could be the biggest boon yet for the 23-year-old ...
The U.S. Food and Drug Administration has approved Alnylam Pharmaceuticals drug Amvuttra to treat transthyretin amyloid ...
Alnylam Pharmaceuticals' shares rose more than 10% on Friday after the drugmaker secured U.S. approval for its heart disease drug, setting the stage for the 23-year-old biotech's next phase of growth.
Alnylam’s drug, vutrisiran, was approved for patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, to reduce ...
Heart disease patients now have another treatment option. The U.S. Food and Drug Administration has approved Alnylam ...
Alnylam Pharma (ALNY) stock rocketed higher on Friday after the pharmaceutical company received approval from the U.S. Food and Drug ...
Alnylam has the FDA approval it sought for Amvuttra in a form of cardiomyopathy associated with rare disease ATTR amyloidosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback